Author at Microdose

Phillips Lytle

Phillips Lytle has a deep and broad knowledge of the regulatory and legal issues related to approval, marketing and use of medications to treat mental health conditions, having served as national science counsel for a global pharmaceutical company for over twenty years.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Law & Politics

1 Jul 2023

FDA Draft Guidance on Clinical Trials for Psychedelics: A Closer Look

This is the FDA’s first guidance focusing on psychedelic drug development. Phillips Lytle law firm takes a closer look....

By Phillips Lytle

Industry, Science

22 Sep 2022

APA Issues Position Statement on Psychedelics

This past July, America’s oldest medical association, the American Psychiatric Association (APA), released an official position statement related to psychedelics entitled “Position Statement on the Use of Psychedelic and Empathogenic...

By Phillips Lytle

Law & Politics

19 Aug 2022

BIPOC Patients Underrepresented in Ketamine Trials

Black, Indigenous and People of Color (BIPOC) experience rates of mental health disorders equal to or greater than non-Hispanic Whites, yet lack access to therapies and are underrepresented in emerging...

By Phillips Lytle

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Phillips Lytle has a deep and broad knowledge of the regulatory and legal issues related to approval, marketing and use of medications to treat mental health conditions, having served as national science counsel for a global pharmaceutical company for over twenty years.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads